Jaguar Health provided updates regarding commercial, educational and product development programs and 2017 results. Effective July 31, 2017, Jaguar merged with Napo Pharmaceuticals and acquired its first-in-class, FDA-approved anti-secretory human prescription drug product, Mytesi. For the period August 1, 2017 through December 31, 2017, preliminary sales of Mytesi were approximately $1.4M. During the aforementioned period, Mytesi sales increased more than 78% relative to average monthly Mytesi sales that took place from January through July of 2017, which is before marketing efforts were deployed in the combined company and the deployment in Q4 of Napo's team of nine sales reps. Napo has accepted a request for support submitted by Dr. Mohamad Miqdady, Chief of Pediatric Gastroenterology, Hepatology and Nutrition at Sheikh Khalifa Medical City in Abu Dhabi, for an investigator-initiated trial of crofelemer, the active pharmaceutical ingredient in Mytesi, for congenital diarrheal disorders in children. Napo intends to submit documentation in the first half of 2018 to the FDA for the planned formulation of crofelemer appropriate for feeding tube administration to support this investigation.
